



# RESI EUROPE 2025

April 1: Barcelona Catalonia Spain | April 2-3: Virtual Partnering



**PRESENTED BY**



**LIFE SCIENCE  
NATION**

Connecting Products, Services & Capital

**ONSITE GUIDE**

Capital investors, licensing partners, fundraising CEOs, and  
service providers **Make a Compelling Connection**

**CO-ORGANIZER**

**TITLE SPONSOR**



RESIConference.com | The InterContinental Barcelona  
#RESI #RESIEUROPE



# RESI 2025 - 26 CONFERENCE SERIES



## RESI BOSTON 2025

JUNE 16: THE WESTIN COPLEY PLACE, BOSTON  
JUNE 17-18: VIRTUAL PARTNERING



## RESI BOSTON 2025

SEPT 17: THE WESTIN COPLEY PLACE, BOSTON  
SEPT 18-19: VIRTUAL PARTNERING



## RESI LONDON 2025

DEC 4: 11 CAVENDISH SQUARE, LONDON  
DEC 5-6: VIRTUAL PARTNERING



## RESI JPM 2026

JAN 12-13: SAN FRANCISCO MARRIOTT MARQUIS  
JAN 14, 19 & 20: VIRTUAL PARTNERING

Take \$100 off with discount code **RESI100** for future RESIs.

For more information about our future events,  
visit our website [RESIConference.com](https://RESIConference.com) or contact us at [RESI@lifesciencenation.com](mailto:RESI@lifesciencenation.com).



## CONTENT

# RESI EUROPE 2025

• Welcome to RESI -----	1
• Floor Plan -----	2
• RESI Agenda -----	6
• Sponsors & Exhibitors -----	10
• Partnering Forum -----	15
• Investor Panels -----	16
• Innovator's Pitch Challenge -----	23
• Entrepreneur's Workshops -----	36

# WELCOME TO RESI



Welcome to RESI Europe 2025 in Barcelona!

Life Science Nation (LSN) is pleased to bring together the global life science investment community for Redefining Every Stage of Investment (RESI) Europe at the InterContinental Hotel in Barcelona. This year's conference highlights the rapidly growing life science innovation ecosystem in Europe, providing a platform for life science companies to connect with investors and strategic partners.

The RESI Europe agenda on Monday, April 1, is packed with opportunities. Each hour will feature insightful investor panels, two Innovator's Pitch Challenge (IPC) tracks, and hands-on workshops. The IPC gives startups the chance to pitch live to an audience and a panel of experienced investor judges.

LSN extends its appreciation to our co-organizer: Biocat, title sponsor: BioMetas, and our sponsors: Gold Sponsors Medmarc and the European Innovation Council, and Silver Sponsor Cein. Their support helps facilitate meaningful connections between investors and innovators.

At its core, RESI is about matchmaking life science companies with the right capital, licensing, and channel partners. The RESI partnering platform enables targeted, high-value meetings based on key criteria, ensuring productive conversations. In-person partnering takes place on Monday, April 1, with virtual meetings continuing through Wednesday, April 3 - maximizing your opportunities to connect.

We look forward to helping you advance your fundraising and strategic goals through RESI!

## **Sougato Das**


President and Chief Operating Officer

Life Science Nation





# InterContinental Barcelona



- 8AM: Registration Opens
- 8-9AM: Breakfast (Foyer)
- 9AM-5PM: Partnering Meetings
- 9AM-4PM: Investor Panels
- 9AM-4PM: Pitch Session Track 1
- 9AM-3PM: Pitch Session Track 2
- 9AM-5PM: Workshops
- 12-1PM: Lunch Break
- 5-7PM: Reception



SSID: RESI\_Europe  
PW: resi2025

# Verdi (Ballroom)

- 1 BioMetas
- 2 & 3 LSN
- 4 Biocat
- 5 ASEBIO
- 6 ASBTEC
- 7 3P Biovian
- 8 Revnuu
- 9 Sterling Pharma Solutions
- 10 European Innovation Council (EIC)
- 11 CEIN Navarra
- 12 OPIS
- 13 Collaborative Drug Discovery

- 1 ADmit Therapeutics
- 2 Flomics
- 3 Ephion Health
- 4 MOWOOT
- 5 Porous
- 6 Altratech
- 7 myBiometry
- 8 Geneial
- 9 MiWendo Solutions
- 10 GAT Biosciences
- 11 Robopedics
- 12 Point Pressure
- 13 Excellgraft
- 14 Anaconda Biomed
- 15 NIMBLE Diagnostics
- 16 Time Is Brain
- 17 CCRP Therapeutics
- 18 Ablevia
- 19 4TISSUE
- 20 BoydSense
- 21 OncoLize
- 22 Telara Pharma
- 23 Cebiotex
- 24 Ahead Therapeutics
- 25 Betternostics
- 26 Eversens
- 27 Leadartis
- 28 Amarna Therapeutics
- 29 Endoply
- 30 Kardi AI
- 31 CYTO365
- 32 TripleMed
- 33 Simplexia
- 34 Ysium Medical
- 35 Opportunity Health
- 36 DARWIN Biomed
- 37 Interlinked
- 38 Rhythm Biotherapeutics
- 39 Cellevate AB
- 40 ArthroSave
- 41 NWPharmaTech Ltd
- 42 Sensars
- 43 Samplix
- 44 NEWRO



# EXHIBIT TABLES



Table #1



Table #2&3



Table #4



Table #5



Table #6



Table #7



Table #8



Table #9



Table #10



Table #11















































Table #12



Table #13



# INNOVATOR'S PITCH CHALLENGE COMPANIES

 <p>Table #1</p>	 <p>Table #2</p>	 <p>Table #3</p>	 <p>Table #4</p>	 <p>Table #5</p>
 <p>Table #6</p>	 <p>Table #7</p>	 <p>Table #8</p>	 <p>Table #9</p>	 <p>Table #10</p>
 <p>Table #11</p>	 <p>Table #12</p>	 <p>Table #13</p>	 <p>Table #14</p>	 <p>Table #15</p>
 <p>Table #16</p>	 <p>Table #17</p>	 <p>Table #18</p>	 <p>Table #19</p>	 <p>Table #20</p>
 <p>Table #21</p>	 <p>Table #22</p>	 <p>Table #23</p>	 <p>Table #24</p>	 <p>Table #25</p>
 <p>Table #26</p>	 <p>Table #27</p>	 <p>Table #28</p>	 <p>Table #29</p>	 <p>Table #30</p>
 <p>Table #31</p>	 <p>Table #32</p>	 <p>Table #33</p>	 <p>Table #34</p>	 <p>Table #35</p>
 <p>Table #36</p>	 <p>Table #37</p>	 <p>Table #38</p>	 <p>Table #39</p>	 <p>Table #40</p>
 <p>Table #41</p>	 <p>Table #42</p>	 <p>Table #43</p>	 <p>Table #44</p>	

# AGENDA

8 - 9 AM: Breakfast (Main Level - Foyer)

9 AM - 5 PM: Partnering Forum (Main Level - Verdi)

**Investor Panels**  
(Main Level - Vivaldi 1)

**Innovator's Pitch Challenge (IPC)**

**Track 1**  
(Main Level - Rossini 1)

**Track 2**  
(Main Level - Rossini 2)

**Entrepreneur's Workshops**  
(Main Level - Vivaldi 2)

9:00 AM  
-  
9:50 AM

**MEDICAL DEVICES PANEL**

*Latest Trends in Medtech Investments*

**IPC SESSION #1**  
**THERAPEUTICS**

**IPC SESSION #7**  
**DIAGNOSTICS**

 **LIFE SCIENCE NATION**  
Connecting Products, Services & Capital  
**IT ALL STARTS WITH YOUR STORY**

10:00 AM  
-  
10:50 AM

**CROSS BORDER INVESTMENTS PANEL**

*Fueling Growth for Global Markets*

**IPC SESSION #2**  
**MEDICAL DEVICES**

**IPC SESSION #8**  
**DEVICES & DIGITAL HEALTH**

 **THE EUROPEAN INNOVATION COUNCIL (EIC)**

11:00 AM  
-  
11:50 AM

**CORPORATE VC PANEL**

*Strategic Capital for Bold Innovations*

**IPC SESSION #3**  
**MEDICAL DEVICES**

**IPC SESSION #9**  
**DIAGNOSTICS**

 **ROUND TABLE : HEALTHTECH MARKET ACCESS PANEL DISCUSSION**

12:00 PM  
-  
1:00 PM

**Lunch Break (-1 Level Diamant)**

1:00 PM  
-  
1:50 PM

**DIGITAL HEALTH PANEL**

*Accelerating the Digital Evolution of Healthcare*

**IPC SESSION #4**  
**THERAPEUTICS**

**IPC SESSION #10**  
**MEDICAL DEVICES**

**TALES FROM THE ROAD**  
*Biotech and MedTech Innovators on their Fundraising Journey*

2:00 PM  
-  
2:50 PM

**SEED FUNDS PANEL**

*Catalysts for Early Stage Technologies*

**IPC SESSION #5**  
**BIOTECH THERAPEUTICS**

**IPC SESSION #11**  
**THERAPEUTICS & MEDICAL DEVICES**

 **VENTURE VALUATION**  
GLOBAL VALUATION SERVICES  
**COMPANY VALUATION FOR FUNDRAISING**

3:00 PM  
-  
3:50 PM

**THERAPEUTICS INNOVATIONS PANEL**

*Biotech Investors Seeking Transformative Therapies*

**IPC SESSION #6**  
**MEDICAL DEVICES**

 **CUATRECASAS**  
**TERM SHEETS**

4:00 PM  
-  
4:50 PM

 **LIFE SCIENCE NATION**  
Connecting Products, Services & Capital  
**INVESTOR LANDSCAPE**

5:00 - 7:00 PM: Cocktail Reception - Announce IPC Winners (Main Level - Jardin)

[biometasgroup.com](http://biometasgroup.com)

**Our CRO is based in  
Shanghai with  
Boston presence,  
offers robust  
biological assays to  
pharma and  
biotech**

**Our customer-first  
approach ensures  
high-quality data  
with fast cycle-  
time**







**biocat**

# Why Barcelona

The BioRegion of Catalonia

**Discover one of the fastest growing  
Health and Life Sciences hubs in Europe**

Check the most  
relevant innovation  
indicators in the **2024  
Catalonia Life Sciences  
and Healthcare Report**



Find investable  
startups, projects  
and investors in our  
matchmaking **Health  
Investment Portal**



Dive into the  
**Catalonia Database  
Sector Platform**  
(+1800 companies and  
research organizations)



**[www.biocat.cat](http://www.biocat.cat)**





# Insuring the Life Sciences Industry Since 1979

- Products Liability
- Clinical Trials Liability
- Manufacturers E&O

Phone: 888.633.6272 | Email: [MedTechLifeSci@medmarc.com](mailto:MedTechLifeSci@medmarc.com)  
4795 Meadow Wood Lane | Suite 335 West | Chantilly, VA 20151

**LEARN MORE**  
**[medmarc.com](http://medmarc.com)**

## SPONSORS & EXHIBITORS

### Co-organizer



### Title Sponsor



### Gold Sponsors



### Silver Sponsor



### Exhibitors





# SPONSORS & EXHIBITORS



Biocat is the driving force behind the healthcare innovation ecosystem in Catalonia, working to scale and consolidate the life sciences and healthcare sector, generating social and economic impact, and positioning the BioRegion of Catalonia as an international benchmark. Established in 2006 at the initiative of the Government of Catalonia and the Barcelona City Council, Biocat is a public-private foundation

with governance bodies comprising representatives from all stakeholders, both public and private.  
[biocat.cat](http://biocat.cat)



## BioMetas: Supporting the Next Generation of Therapeutic Startups

BioMetas is a trusted partner for early-stage biotech innovators, providing a comprehensive suite of preclinical research services. With expertise spanning in vitro biology, in vivo pharmacology, cancer biology, protein science, and immunology, BioMetas enables startups to progress their drug development programs efficiently. By streamlining the preclinical process and providing milestone-driven support, BioMetas helps biotech companies de-risk their assets and position them for successful global partnering opportunities.



Created in 1979 by the healthcare technology industry, Medmarc's mission is to be the superior provider of liability insurance protection and related risk management solutions to the medical technology industry. We support the research and development, manufacturing, and delivery of medical products that save lives and improve the quality of life. Through collaboration with our parent company, ProAssurance, and our strategic alliance carriers in the U.S. and abroad, we provide a single source of innovative healthcare liability insurance solutions to the life sciences companies we serve. From ideas and prototypes to the reality of commercialization and success – We Can Meet Your Changing Needs. Contact us to discuss the cost of insurance coverage and what coverages are needed for your business plan. (703) 652-1360



The European Innovation Council (EIC) is the EU's flagship program under Horizon Europe, with a €10.1 billion budget (2021–2027) to support breakthrough technologies and high-impact innovations. It funds early-stage research through EIC Pathfinder, technology maturation via EIC Transition, and market scaling for startups and SMEs with EIC Accelerator, which offers grants and equity investments. Beyond funding, the EIC provides Business Acceleration Services, including mentoring and global networking. Managed by the EIC Board and EISMEA, it fosters disruptive innovation across Europe. Learn more at [eic.ec.europa.eu](http://eic.ec.europa.eu).

## SPONSORS & EXHIBITORS



The Centro Europeo de Empresas e Innovación de Navarra (CEIN) is a public non-profit organization backed by the Government of Navarra. It fosters regional economic growth by promoting entrepreneurship, supporting startups, and driving innovation in SMEs. CEIN helps entrepreneurs develop scalable businesses, particularly in strategic sectors, through advisory services and incubators. In 2024, CEIN supported the creation of 95 new companies, generating 260 jobs, and provided guidance on 474 projects. It also organized 450 initiatives with around 3,700 participants. The organization operates innovation incubators in Noáin (general innovation) and Tudela (agri-food innovation), along with an office in Pamplona. Through tailored programs, CEIN enhances business sustainability and competitiveness, strengthening Navarra's entrepreneurial ecosystem.



Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organize and analyze both biological and chemical data, and to collaborate with partners through a straightforward web interface. CDD Vault helps scientists register entities, track inventory, manage bioassay data, capture experiments, calculate Structure-Activity Relationships (SAR), and mine their data for drug candidates. It also functions as an Electronic Laboratory Notebook (ELN) to capture and share experimental results. CDD Vault is differentiated through its intuitive design, superior performance, and workflows for secure, collaborative data sharing capabilities. CDD was founded in 2004 and presently serves thousands of researchers doing drug discovery all around the world. Learn more at [www.collaborativedrug.com](http://www.collaborativedrug.com)



AseBio, the Spanish Bioindustry Association, unites companies, associations, foundations, universities, and research centers in biotechnology. Collaborating with governments and social organizations, AseBio promotes science, environmental sustainability, economic development, and high-value employment. For 25 years, AseBio has driven political and economic changes to advance Spanish biotechnology, enhancing quality of life and economic competitiveness. Committed to innovation, AseBio fosters an inclusive ecosystem to address social and generational challenges. As a member of EuropaBio, AseBio represents the interests of over 1,800 European companies, emphasizing cooperation and network collaboration to achieve its goals.



The Associació de Biotecnòlegs de Catalunya (ASBTEC) is a non-profit organization founded in 2005 to support biotechnology professionals and students in Catalonia. It promotes the role of biotechnologists, advocates for quality education, and fosters professional development through networking, workshops, and the annual Jornades de Biotecnòlegs de Catalunya. ASBTEC collaborates with universities like UAB, UB, UVic, and URV and partners with organizations such as the Col·legi de Biòlegs de Catalunya to enhance career opportunities. The association plays a key role in connecting members with industry, facilitating knowledge exchange, and strengthening Catalonia's biotech sector.

## SPONSORS & EXHIBITORS



OPIS provides full-service, 360° clinical trial support from study concept creation and protocol development to full project execution, study data handling and up to study closure, analysis, and reporting. We manage Phase I-IV, interventional, non-interventional and medical devices studies on an international level. In addition, OPIS also manages pre- and post-marketing clinical investigations for medical and diagnostic devices, nutraceutical, and food supplement studies.



Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) with more than 55 years' experience in providing small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries. Sterling manages the most complex API and API intermediate challenges from proof-of-concept to commercial manufacture, as well as Antibody Drug Conjugate (ADC) development and manufacturing services, and peptide development and manufacturing services. At Sterling we believe that whilst science can be complex, partnerships should be simple. That's why we have redefined the CDMO experience with a partnership centred approach marked by transparency, collaboration and trust; a Partnership Development and Manufacturing Organisation (PDMO®). Sterling has six facilities employing more than 1,350 people: its HQ in Cramlington and a site in Newcastle, UK; a facility in Cork, Ireland; sites in North Carolina and Wisconsin, US; and a dedicated bioconjugation and ADCs facility in Deeside, Wales. For more information visit [www.sterlingpharmasolutions.com](http://www.sterlingpharmasolutions.com) | LinkedIn: [/sterling-pharma-solutions](https://www.linkedin.com/company/sterling-pharma-solutions)



3PBIOVIAN is a globally operating Contract Development and Manufacturing Organization (CDMO), delivering end-to-end services for biotech and pharma companies. Their service offerings include protein expression and production platforms based on microbial strains and mammalian cells, plasmid DNA, viral vectors for adenovirus and adeno-associated virus for gene therapy, and cell therapy products. Additionally, they provide fill and finish services for recombinant proteins and viral vectors. The company has manufacturing facilities in Pamplona-Noáin, Spain, and Turku, Finland, efficiently supporting the diverse needs of their clients, covering everything from preclinical and clinical supply to large-scale commercial manufacturing for drug substance and drug product. [www.3pbiovia.com](http://www.3pbiovia.com)



At Revnuu, we specialize in empowering businesses to focus on their core operations while we expertly manage their brand development and revenue generation in the digital age. Our mission is to drive your success through our tailored B2B marketing and business development strategies. With a proven track record of delivering measurable results, we provide: Comprehensive Marketing Solutions: We craft data-driven marketing campaigns that resonate with your unique target audience, enhance brand visibility, create demand, and create long-lasting brand equity. Strategic Business Development: Our team leverages industry-leading technology and processes to identify growth opportunities, design and implement Demand Generation processes, and expand your market presence. Digital Transformation: We guide you through the ever-evolving digital landscape, helping you adapt and thrive in a rapidly changing business environment. Partner with us to unlock your business's full potential and stay ahead in today's competitive marketplace. Let's grow together!



# RESI CONFERENCE SERIES PRESENTED BY LIFE SCIENCE NATION

Life Science Nation (LSN) has built a global partnering ecosystem featuring healthcare startups and the capital investors, co-development, and licensing partners who seek them. LSN accelerates the fundraising journey by bridging the gap between early-stage entrepreneurs, capital investors, and licensing partners.

- LSN's GPC Platform and RESI Conference Series are invaluable resources for sourcing partners based on product, stage of development, and allocation requirements. These resources are curated regularly and allow for dynamic matching based on fit.
- This one-of-a-kind partnering ecosystem is unique because it is cross-domain, serving the silos of Drugs, Devices, Diagnostics, and Digital Health (the 4Ds).
- The LSN platform also includes relationships with the service providers, tech hubs, and government agencies that provide the international infrastructure that makes the early-stage life science industry run.
- LSN's partnering platform has three components:
  1. Capital and Licensing Partner data profiles integrated with Salesforce CRM
  2. RESI Partnering Events
  3. Entrepreneurial Education and Roadshow Preparation



## Global Partnering Campaign (GPC), Fundraising & Licensing Partner Roadshow Management.

The GPC integrates LSN's Investor and Licensing Partner Database and the Salesforce CRM. Subscribing companies receive a vetted Global Target List (GTL) of likely partners garnered through one-on-one interviews with the LSN research team, which can be organized into three tiers of Investor Priority:

- Tier 1: Partner is matched on a specific mandate.
- Tier 2: Partner is matched on an opportunistic mandate seeking compelling technology assets.
- Tier 3: Partner is matched as a potential fit based on past or recent actions. This is where the numbers game comes into play.

Information on these profiles is automatically updated daily, and user outreach and tasks can be tracked intuitively with CRM components, including the following:


- Status of Outreach (Lead, Reviewing Materials, Call/Meeting Scheduled, etc.)
- Materials Sent (Executive Summary, Pitch Deck, etc.)
- Notes (NDA status, DD, and data room)
- Reporting (investor/licensing pipeline)



Life Science Nation's (LSN) publications offer a current dialogue for life science fundraising companies to sharpen the skills needed to create a compelling fundraising campaign. These publications include education on how to increase fundraising and marketing efforts for their organization or affiliated startups, expert interviews, event announcements, and active investor mandates. Subscribe and stay up-to-date with meaningful insight into raising capital in the life science industry.



## NEXT PHASE»



# PARTNERING FORUM

Location: Verdi (Main Level)


## APRIL 1: IN-PERSON PARTNERING MEETING APRIL 2-3: VITURL PARTNERING MEETING

Investor/In-licensor Type	Percentage
Venture Capital	27%
Angel & Family Office	19%
Big Pharma & Medtech	17%
Corporate VC	14%
Others	8%
Endowments/Foundations	6%
Government Organizations	9%

Company Type	Percentage
Therapeutics	47%
Medical Device	32%
Diagnostics	16%
Digital Health	5%

Service Provider Type	Percentage
Professional Services	39%
CRO/CMO	30%
Non-Profit	18%
Suppliers	8%
Others	5%

### Who Meets with Whom at RESI Conferences



RESI provides a partnering forum for stakeholders across all stages of the life science ecosystem to connect and build relationships that drive new technologies toward commercialization.



# 9:00 AM - 4:50 PM | INVESTOR PANELS

Location: Vivaldi 1 (Main Level)

## Moderator & Panelists

9:00 - 9:50 AM

### MEDICAL DEVICES PANEL

*Latest Trends in Medtech  
Investments*

**Florence Thueux**, President & CEO, M2Care 

**Santiago Lozano**, Healthtech Funds Director, Clave Capital

**Harold Mennen**, Investment Associate, TCD Capital

**Daniel O'Mahony**, Partner, Seroba Life Sciences

**Sanchita Pasi**, Investor, EQT Life Sciences

10:00 - 10:50 AM

### CROSS BORDER INVESTMENTS PANEL

*Fueling Growth for Global  
Markets*

**William Pay**, Venture Partner, Winhealth Pharma 

**Simon Hua**, Chairman, BioMetas

**Erki Mölder**, Managing Partner, Verge Health Tech Fund

11:00 - 11:50 AM

### CORPORATE VC PANEL

*Strategic Capital for Bold  
Innovations*


**Jose Vicente Terencio**, VP, Grifols Innovation And New Technologies, Grifols

**Louise Warme**, Head of We Venture Capital, We Venture Capital

1:00 - 1:50 PM

### DIGITAL HEALTH PANEL

*Accelerating the Digital  
Evolution of Healthcare*

**Jorge Blasco**, Venture Partner (Spain), Lumo Labs 


**Nils Bottler**, Principal (Berlin), Angelini Ventures

**Geoffrey D'hondt**, Investment Director, Heran Partners

2:00 - 2:50 PM

### SEED FUNDS PANEL

*Catalysts for Early Stage  
Technologies*

**Jordi Ferrer**, Healthcare Investment Director, Ship2B Ventures 

**Matthieu Coutet**, Partner, Biovelocita Strategy, Sofinnova Partners

**Lina Gaydarova**, Investment Manager, Novaterra

**Luis Pareras**, Managing Partner, Invivo Partners

3:00 - 3:50 PM

### THERAPEUTICS INNOVATIONS PANEL

*Biotech Investors Seeking  
Transformative Therapies*

**Jim McGough**, Managing Partner, Mid Atlantic Bio Angels 

**Carla Benichou**, Senior Investment Analyst, RV Invest GmbH

**Laura Rodriguez**, Partner, Invivo Partners

**Artemy Shumskiy**, Senior Associate, LongeVC

 Moderator

# 9:00 AM | MEDICAL DEVICES PANEL

## *Latest Trends in Medtech Investments*

The medical device industry continues to experience rapid growth, driven by technological innovation, regulatory advancements, and increasing global healthcare demand. This panel brings together active investors to discuss the latest trends, opportunities, and challenges in the medical device industry.

Topics addressed may include:

- Emerging technologies and current trends that excite investors
- Investment strategies and due diligence process on medical device opportunities
- Navigating regulatory hurdles and barriers to market entry
- Case studies of successful medical device investments

This panel will be an insightful discussion on how investors capitalize on this dynamic sector while driving advancements in patient care and medical technology.

### **Florence Thueux, President & CEO, M2Care**

Florence has a dual experience as an entrepreneur and an investor in the healthcare sector. She has participated in the start-up, development and sell out of several companies, in positions of CFO then CEO and President, in roles of growth structuring, negotiation of deals, architecture of business' and equity's partnerships, M&A, strategy and management (Arrow Génériques, Etat Pur -3rd brand of the Naos Group-, BePatient, etc.) She has navigated between the world of startups and that of Corporates (Merck KGAA, Cephalon, etc.), between industry and investment (partner for 6 years at Remora Capital) and between France and Europe (UK, Portugal, Switzerland in particular). She has advised several Health investment funds and sat on the Board of investment funds and startups, as well as the French BPI in its Accelerator ETI program. Florence is a graduate of Emlyon business school and DSCG (Master of Finance equivalent).



### **Santiago Lozano, Healthtech Funds Director, Clave Capital**

Santiago Lozano is the Tech Transfer Venture Funds Director at Clave Capital, a venture capital firm with a long background and experience in venture investment focused on tech deals (specially tech transfer projects) in early stage, mainly in three verticals, health, engineering, and agrifood. He has been working in venture capital for 20 years in Clave Capital, promoting different funds with a total size of 64 Million euros and taking part in many Startups boards and valorization processes since 2005, with special focus on health sector.



### **Harold Mennen, Investment Associate, TCD Capital**

Harold Mennen is a Senior Associate at TCD Capital, where he has been actively investing in Life Sciences for the past three years. His focus spans MedTech, digital health, and select biotech opportunities. Investing tickets between 1-5M with optional co-investments from LP's in Belgian and French Series A stage companies. His life science investment track record includes Clouds of Care, MyNEO, Synergia Medical, and Lys Therapeutics.



### **Daniel O'Mahony, Partner, Seroba Life Sciences**

Daniel O'Mahony is a Partner at Seroba and brings a wealth of experience in product development, strategic planning, licensing, corporate venturing, intellectual property management and commercialisation. Daniel was involved in corporate venture at Elan Corporation from 1996-2003. He was an advisor and consultant to Kernel Capital venture capital fund from 2001 and a partner from 2008, focusing on investments in life sciences. He joined Seroba as partner in 2009. Daniel has held academic appointments at the Genetics Department, Trinity College, Dublin, the Weis Research Centre, Geisinger Clinic, Pennsylvania, USA, and the Department of Medicine & Experimental Therapeutics at University College Dublin. He established Technology Transfer Office at University of Galway, leading to several lucrative licensing deals (2005-2007). He has published in several scientific journals and is co-inventor on numerous patent families.



### **Sanchita Pasi, Investor, EQT Life Sciences**

Sanchita Pasi is a healthcare investment professional at EQT Life Sciences, where she focuses on MedTech, Diagnostics, and Digital Health innovations that aim to enhance the quality of care and deliver strong health economic outcomes. With a solid foundation in early-stage investments from her time at Sagana and Nina Capital, Sanchita has supported the growth of innovative health-tech companies globally. Her experience at Abbott Laboratories, where she worked in product management and market development across the EMEA region, provided her with a broad perspective on healthcare operations and commercialization strategies. Sanchita holds a PharmD and an MBA from SDA Bocconi. Combining her clinical background with business acumen, she is committed to investing in solutions that tackle critical global health challenges.





# 10:00 AM | CROSS BORDER INVESTMENTS PANEL

## *Fueling Growth for Global Markets*

As global markets become increasingly interconnected, cross-border investments between US, Europe, and beyond are unlocking new opportunities for growth. This panel brings together experienced investors, legal experts, and industry leaders to explore the complexities of international investments and strategies for navigating regulatory, economic, and geopolitical challenges.

Topics addressed may include:

- The importance of fostering cross-border investment and partnership opportunities in the life sciences & healthcare industry
- Strategies for mitigating risks and optimizing cross-border deal structures
- How current economic trends are shaping international investment flows
- Examples of successful cross-border deals

This panel will be an in-depth discussion on how investors can successfully expand their portfolios, how companies can better seek to work with these global investors, leverage international opportunities, and navigate the evolving global investment landscape.

### **William Pay, Venture Partner, Winhealth Pharma**



William joined Pappas Capital as a Venture Partner in 2023. Previously, he was the Founding Managing Director for Asia at Bryan Garnier & Co., a leading European investment bank. William has advised EPS Holdings, a major clinical CRO in Japan, and serves as an advisor to WinHealth Pharma Group, focusing on rare diseases in Greater China. Before transitioning to investment, he worked at Bayer Healthcare as Chief of Strategic Sourcing, managing a half-billion-euro supply chain. William's career spans 25+ years at companies like Takeda, Johnson & Johnson, Pfizer, and Quintiles. He is a member of BayHelix Group and is fluent in English and Mandarin, based near Shanghai.

### **Simon Hua, Chairman, BioMetas**



Simon Hua is the Chairman of BioMetas Group, a leading CRO based in Shanghai, and the Chairman of China Finance Strategies Investment Holdings, a Hong Kong-based investment group. He was previously a Co-Founder of Viva Biotech, a globally recognized CRO. With a strong background in both the life sciences and financial sectors, Simon has extensive experience in investment strategy, business development, and corporate leadership. He holds an MBA in Finance from the International University of Japan.

### **Erki Mölder, Managing Partner, Verge Health Tech Fund**



Erki has been active in the healthcare and life sciences sector for over two decades, beginning in 1999 when he became CEO of Quattromed. Over the next 14 years, he led the company's transformation from a University of Tartu spin-off into the largest regional laboratory, operating across three countries with a team of over 200 employees. In 2013, Quattromed was acquired by Synlab. Since 2013, Erki has been actively investing in early-stage healthtech companies, leveraging his deep industry expertise. In addition to Quattromed, he has successfully led investments resulting in two additional exits in the healthtech space. He is also the Founder of the Health Economy Association (2019) and Health Founders (2020)—the first business accelerator in the region focused on healthtech innovation. In 2019, Erki joined Verge HealthTech Fund as a Venture Partner for Europe, and in 2022, he became a Managing Partner, driving investments in groundbreaking healthcare technologies globally.

# 11:00 AM | CORPORATE VC PANEL

## *Strategic Capital for Bold Innovations*

Many large corporations establish corporate venture or innovation arms to invest and partner with life science and healthcare companies. However, every corporate venture capital firm has a unique approach and strategy in investment, and their ties to the corporation can differ. Some invest only in areas that complement the parent company's existing interest areas, while some may source for opportunities beyond those interest areas. This panel will uncover insights from active corporate VC firms and how they seek to drive innovation, accelerate R&D, and bring transformative solutions to market.

Topics addressed may include:

- How CVCs align investments with corporate strategy in healthcare & life sciences
- Balancing financial returns with long-term patient and industry impact
- The role of CVCs in fostering biotech, medtech, and digital health innovation
- Due diligence & investment process – how can companies seek to work with these firms?

This panel will provide exclusive insights from active corporate VC investors on emerging investment trends, strategic priorities, and the evolving role of corporate venture capital in transforming healthcare.



**Jose Vicente Terencio, VP, Grifols Innovation And New Technologies, Grifols**

VP of Grifols Innovation And New Technologies (GIANT), the external innovation arm of Grifols and CEO of Araclon Biotech. With more than 25yrs+ of experience in the Pharma and Biotech industry he has held different positions in R+D, Innovation and Corporate Venture Capital. Biochemist by training, holds a Master in R+D of Drugs by the University of Navarra, a PhD in Biology by the University of Barcelona, a Development Management Program (PDD) by IESE Business School, and a Master of Financial and Accountability Management by University Pompeu Fabra of Barcelona.



**Louise Warme, Head of We Venture Capital, We Venture Capital**

Louise is the Head of We Venture Capital, with 10+ years of experience in investments in Life Science and board engagements. She has a background as a medical doctor and researcher, and is founding CEO of a medtech startup. Louise also holds a Clinical Innovations Fellowship at Karolinska Institute & Royal Institute of Technology, Stockholm, Sweden. In addition, Louise serves as a director on the board of Axithra and Capitainer and an observer to the board of Deepull and Zetta, our portfolio companies.

# 1:00 PM | DIGITAL HEALTH PANEL

## *Accelerating the Digital Evolution of Healthcare*

The digital health landscape continues to expand rapidly, with a growing emphasis on disease-specific solutions beyond chronic disease management and mental & behavioral health. Reimbursement for digital health companies has been improving and accelerating – digital therapeutics, AI/ML-driven patient monitoring and diagnostics tools are all important technologies that have enormous potential in improving patient outcomes. This panel will bring together active digital health investors to talk about latest trends, opportunities, and challenges in the digital health sector.

Topics addressed may include:

- Emerging technologies and current trends that excite investors
- Investment strategies and due diligence process on digital health opportunities
- Navigating regulatory and reimbursement hurdles
- Examples of successful digital health investments

This panel will provide actionable insights into the evolving digital health investment landscape and its impact on the broader healthcare ecosystem.

### **Jorge Blasco, Venture Partner (Spain), Lumo Labs**



Jorge is a serial entrepreneur and investor, known for his successful exit with Boutique Secret, an e-commerce marketplace for families, sold to Bertelsmann. As a Business Angel, he has invested in over 20 high-tech companies and advises on fundraising and M&As through his firm, The Net Street. He's now a Venture Partner at LUMO LABS, focusing on tech companies that improve life quality, healthcare, and the planet. With an engineering degree from UPC and an MBA from ESADE, Jorge is a frequent public speaker and lecturer at ESADE, where he teaches entrepreneurship. He's also the author of an Insurtech book for startup entrepreneurs in the insurance industry.

### **Nils Bottler, Principal (Berlin), Angelini Ventures**



Nils is a Venture Capitalist at Angelini Ventures, the venture capital arm of Angelini Industries, focusing on strategic early-stage investments in the health, life sciences. He has worked in venture capital for over 10 years and has held management positions at life science, digital health and healthcare services companies. Combining an operator's know-how with an investor's foresight, Nils invests at the intersection of healthcare and technology.

### **Geoffrey D'hondt, Investment Director, Heran Partners**



Geoff serves as Investment Director at HERAN Partners, a Belgium-based VC firm with a focus on enabling technologies in the healthcare space. He gained first experience in investment management at Gimv before joining Valiance where he built a track record in venture-backed healthcare investments, both in Europe and the US. Geoff holds a Master's in Business Economics from Ghent University (Belgium) and an Advanced Master's in Finance from ESCP Europe (Paris, France).

## 2:00 PM | SEED FUNDS PANEL

### *Catalysts for Early Stage Technologies*

Seed funding plays a pivotal role in translating scientific research into impactful healthcare solutions, providing crucial capital for early-stage product development, clinical trials, and regulatory preparations. This panel will bring together seed investors with expertise in various life science and healthcare sectors to discuss how they support startups through the initial stages of research, prototype development, and navigating regulatory pathways.

Topics addressed may include:

- The role of seed investors and the impact they have on the early-stage life sciences and healthcare ecosystem
- Strategies on due diligence and assessment in early-stage opportunities, especially on identifying ventures with high potential and navigating risk
- Particular areas of interest within life sciences and healthcare
- Approaches that funds take to help seed stage companies to scale and grow

Seed funds are important catalysts in fostering early stage innovations, and this panel will be an insightful panel on learning more from those that invest in the earliest stage opportunities.



**Jordi Ferrer, Healthcare Investment Director, Ship2B Ventures** 

With over 12 years of global experience in healthcare, Jordi is passionate about value-based care and how technology can significantly improve access to care as well as people's quality of life. Jordi currently leads healthcare investments at Ship2B Ventures, a European Venture Capital firm investing in early-stage startups targeting Ageing and Chronic conditions, throughout the care cycle. Jordi also acts as Board Director in several portfolio companies and is deeply connected to the European ecosystem through various collaborations with healthcare hubs.

**Matthieu Coutet, Partner, Biovelocita Strategy, Sofinnova Partners**

Matthieu Coutet is a Partner at Sofinnova Biovelocita Strategy with nearly 20 years of experience in venture capital and operations. He spent a decade in technology transfer, leading InsermTransfert's New Venture department and managing InsermTransfert Initiative, where he made 14 seed-stage investments. Matthieu also served as VP of Operations and Business Development at TherAchon (acquired by Pfizer) and Annapurna Therapeutics (merged with Adverum). He co-founded AdBio Partners in 2016, raising funds and launching six biotech companies. Matthieu has built a strong network of researchers, entrepreneurs, and professionals. A graduate of ESIEE Management, he values working with teams skilled in science, entrepreneurship, and investment to scale early-stage companies.

**Lina Gaydarova, Investment Manager, Novaterra**

Lina Gaydarova is an early stage life sciences investor at Novaterra, Italy's first international pre-seed & seed impact fund. Lina is based in Milan, and actively invests across biopharma in CNS & oncology as well as wet lab diagnostics in EU/US geographies. Prior to Novaterra, Lina was an investor at Bessemer Venture Partners in San Francisco focused on enterprise and healthcare while executing early stage biopharma oncology investments as an LP in an angel fund. Lina's early career was a mix of investment banking & growth equity across infrastructure technology, which she leveraged as a launchpad to break into early stage life sciences investing.

**Luis Pareras, Managing Partner, Invivo Partners**

Degree and PhD in Medicine (UB), specialist in Neurosurgery and Global Executive MBA (IESE). Founder and Managing Partner of Invivo Partners focused on early-stage investments in the healthcare sector, where he has led the investment strategy and transaction processes. He serves or has served at the Board of Directors of many life sciences companies including Sanifit (acquired by Vifor), Minoryx, Versantis (acquired by Genfit), Glycardial Diagnostics, n-Life Therapeutics, Peptomyc, Arthex, Pulmobiotics, Gyal, Telum, OneChain Immunotherapeutics, Telomere Therapeutics Corteria and Integra. Deeply involved in the innovation ecosystem, he is a member and advisor of many healthcare innovation organizations, and author of numerous books in the field of innovation, venture capital and healthcare, including the recently published "Fast-Forward Thinking". In the academic space, he teaches at several business schools about healthcare innovation and venture capital.

# 3:00 PM | THERAPEUTICS INNOVATIONS PANEL

## *Biotech Investors Seeking Transformative Therapies*

With biotech VC investment in 2024 increasing over 33% compared to the previous year and robust in-licensing activity, this year brings more optimism to the biotech ecosystem. Many investors continue to partner with and invest in biotech companies across various modalities and indications, in hopes of accelerating novel, transformative therapeutics that can impact the lives of patients suffering from debilitating diseases.

Topics addressed may include:

- Emerging trends and therapeutic areas of interest, exciting breakthroughs in major indications
- The role of different types of investors and partners, including traditional VCs and in-licensing partners
- Considerations companies must have to navigate through R&D and properly scale, especially those with platform technologies with potential in multiple indications
- Investment and due diligence process – how do you derisk opportunities, especially when many biotech companies are in pre-clinical and early clinical stage?

Investment and strategic partnering in biotech plays a key role in accelerating therapies and addressing high unmet need. This panel will uncover insights from some of the key players who aim to make an impact by supporting transformative solutions to go to market.

### **Jim McGough, Managing Partner, Mid Atlantic Bio Angels**




Jim McGough is co-founder and Board Member at EdgeOne Medical Inc., a leading global Device Development and Testing Services firm for the pharmaceutical industry. He is also Managing Partner of EdgeOne Venture Partners. Jim's vision for a seamless service provider has been key to EdgeOne's growth, making it a trusted partner in pharma and medtech. An angel investor, he serves as a board member or advisor in several HealthTech and Big Data/AI ventures. Previously, Jim held executive roles at Motorola, Audi, and Citigroup. He pioneered smartphone integration with Bluetooth at Audi. Jim holds a Master's in International Management from Thunderbird and a Bachelor's in History from UC Berkeley.

### **Carla Benichou, Senior Investment Analyst, RV Invest GmbH**




Carla is part of the investment team at RV Invest, where she searches and analyses early-stage investment opportunities in biotech as well as supports the current portfolio. She has 4 years of experience supporting innovative startups through her previous roles, including at the biotech startup accelerator BaseLaunch and the consulting firm Gartner. Carla graduated in Business Administration from ESADE and holds an MSc in Applied Neurosciences from King's College London.

### **Laura Rodriguez, Partner, Invivo Partners**



She is a Partner at Invivo Partners, a venture capital firm focusing on early-stage life sciences companies, where she joined in January 2018. The firm recently launched its third fund, targeting €100 million for investments in advanced therapies. She serves on the boards of OneChain, Telomere Therapeutics, and Esobiotech, and as an Observer at Arthex, Pulmobiotics, Gyala Therapeutics, and Telum. Previously, she worked as a Project Manager at the Research Institute of Vall d'Hebron Hospital in Barcelona. With five years of R&D experience in oncology and gene therapy, she holds a BSc and PhD in Biotechnology and a postgraduate course in Innovation Management from UAB and UB.

### **Artemy Shumskiy, Senior Associate, LongeVC**



Artemy Shumskiy is an experienced researcher with deep experience in molecular and cellular biology and biotechnology. He currently contributes evaluating investment strategies for early-stage biotech and longevity startups. His prior roles included working as a research analyst and bioinformatics scientist at the Longevity Science Foundation and BostonGene, where he applied his expertise to advance research in life sciences. Artemy is also a fellow at the Longevity Biotech Fellowship program and holds a bachelor's degree in Cellular and Molecular Biology from the University of Illinois, as well as a master's degree in Biotechnology from the Skolkovo Institute of Science and Technology.



# 9:00 AM - 3:50 PM | INNOVATOR'S PITCH CHALLENGE TRACK 1

Location: Rossini 1 (Main Level)

## Pitch Company

9:00 - 9:50 AM

### IPC SESSION #1 THERAPEUTICS



Table #24



Table #41



Table #33



Table #22

10:00 - 10:50 AM

### IPC SESSION #2 MEDICAL DEVICES



Table #4



POINT PRESSURE

Table #12



Table #42



timeisbrain

Table #16

11:00 - 11:50 AM

### IPC SESSION #3 MEDICAL DEVICES



4Tissue

Table #19



joint reviving medical treatment

Table #40



Table #11



Table #34

1:00 - 1:50 PM

### IPC SESSION #4 THERAPEUTICS



Table #17



INNOVATION. BIOTECHNOLOGY. LIFE.

Table #23



Table #27



Table #21

2:00 - 2:50 PM

### IPC SESSION #5 BIOTECH THERAPEUTICS



Table #18



Table #28



Table #39



Table #10

3:00 - 3:50 PM

### IPC SESSION #6 MEDICAL DEVICES



Table #31



excellgraft

Table #13



Table #9



Table #43

## 9:00 AM | SESSION 1 - THERAPEUTICS



Focus on developing cure for auto-immune diseases. We have a proprietary nano-technology platform to generate Antigen Specific Immune Tolerance (ASIT), Mimicking the engulfment of the apoptotic cells by APCs. Assets: Myasthenia Gravis; Rheumatoid Arthritis; T1D; Multiple Sclerosis; Celiac Disease; Neuromyelitis Optica; Thrombotic Thrombocytopenic Purpura. We are now in Series A fundraising round of €15M, to put our leading asset until clinical trial phase IIa, plus the continuous platform development (wide pipeline) and the MTA (material transfer agreement) signed with a big pharma company.



NWPharmaTech is a clinical-stage biotech company dedicated to developing innovative treatments for psychiatric and neurological disorders. Building on previously achieved efficacy data, the company is advancing NW300EMCBD into Phase 2 dosing trials in 2025, with its lead indication targeting Clinically High-Risk for Psychosis (CHR-P) - a prodromal stage preceding psychotic disorders. NWPharmaTech's proprietary drug, NW300EMCBD, utilizes micelle delivery technology to enhance cannabidiol (CBD) bioavailability, aiming to provide the first licensed pharmaceutical treatment for CHR-P. Beyond CHR-P, the company is actively expanding its pipeline, exploring applications in parkinson's disease psychosis, behavioural symptoms of dementia, PTSD, anxiety and insomnia. Additionally, NWPharmaTech is advancing new formulations and drug candidates. Through strategic partnerships with academia and the pharmaceutical industry, NWPharmaTech strives to drive innovation in mental health drug development.



Simplexia is a biotech startup based on research from the University of Gothenburg, where our team has developed a vaccine candidate against genital herpes caused by herpes simplex virus 2 (HSV-2). HSV-2 infections are estimated to affect more than 500 million people worldwide. Most previous HSV vaccine candidates have targeted antigens than are common to HSV-1 and HSV-2. Data from these studies suggests that antibodies generated during an earlier HSV-1 infection block responses to common antigens. Simplexia's patented approach is unique in avoiding this problem. Our vaccine target antigen is virus glycoprotein G2 (gG-2), which is specific for HSV-2, and is not blocked by previous infection with HSV-1. Our recombinant gG-2 subunit vaccine protects from both genital and neurological disease and reduces virus shedding in rodent challenge studies. gG-2 also activates human T cells in patient studies. Simplexia is currently fundraising for a phase I/II clinical study with our candidate.



NEUROPROTECTION is currently a huge unmet need and a priority to stop the progression of glaucoma and to prevent blindness. The drug CILASTATIN (CIL) has shown unprecedented NEUROPROTECTION of the retina in gold standard animal models of GLAUCOMA, constituting a disruptive treatment for glaucoma and other neurodegenerative eye diseases. Telara is developing a neuroprotective therapy as CILASTATIN eye drops directly targeting retinal ganglion cells that be an add-on treatment of glaucoma intraocular pressure (IOP)-lowering drugs. We are currently performing the safety preclinical trials with the goal to complete Proof of Concept (POC) clinical trial with glaucoma patients by the end of 2028. Such a treatment would have the potential to improve glaucoma management in the majority of patients and offer hope to those who have exhausted conventional treatment options.

## 10:00 AM | SESSION 2 - MEDICAL DEVICES



MOWOOT has developed Intermittent Colonic Exoperistalsis, the first purely physical, non-invasive and non-drug solution for bowel dysfunctions such as constipation. Driven by pneumatic force and individualized to each patient via real-time pressure sensors, a series of soft robotic elements externally stimulates the large intestine, resulting in healthy bowel movements. Clinically proven with over 13 scientific publications, recommended in clinical guidelines in several EU countries and IP protected by a series of international patents the 'MOWOOT Bowel management System' is already on the market.



At Point Pressure we offer a wearable medical device that helps stroke patients regain mobility and recover from physical disabilities faster and more efficiently. Using our device, patients undergoing treatment experience improvements in balance, strength, speed, and mobility in the affected limbs. Our device modulates the nervous system, enabling the brain to more effectively incorporate new movement patterns. Through targeted mechanical stimulation, it reorganizes the way movement is generated in both cortical and subcortical brain areas, leading to more refined and efficient motor function. This approach is non-pharmacological, non-invasive, and completely painless, without risk of developing tolerance. Paired with our app, we assess patient-specific characteristics to personalize the treatment plan and generate detailed reports tracking progress throughout the therapeutic process, encouraging adherence and enhancing treatment outcomes.



Sensars is revolutionizing diabetic neuropathy care by developing SENSY, the first and only neurostimulation system that restores natural sensation from the feet. Unlike existing neuromodulation solutions that only mask pain, SENSY uses intraneural stimulation via microwires implanted inside the sciatic nerve, enabling patients to adjust gait, prevent ulcers (and subsequent amputations), reduce falls, and relieve pain. The system includes a sensorized insole and an implantable neurostimulator, providing real-time sensory feedback that reestablishes communication between the feet and the brain. Our solution offers unique value across stakeholders: surgeons gain a new revenue stream, endocrinologists retain patient management post-surgery with reimbursed telemonitoring, and payors save up to \$356,250 per patient by preventing deaths and costly complications. Sensars holds exclusive IP, has secured an FDA Breakthrough Device Designation, and is advancing toward PMA approval, targeting a \$40 billion market opportunity in the EU and USA.



Time is Brain (TiB) is an innovative technology-driven startup born from the visionary minds of leading neurologists at Germans Trias i Pujol Comprehensive Stroke Center: Dr. Alicia Martínez (CEO), Dr. Antonio Dávalos (CSO and renowned Key Opinion Leader) and Dr. Jaume Coll Cantí. In 2013, they started a groundbreaking research journey that culminated with the development of the Brain20®, the only medical device capable of real-time brain monitoring for acute stroke patients. While TiB's current focus lies in revolutionizing stroke care, our overarching mission is to pioneer new tools that enhance outcomes across a spectrum of neurological disorders.

## 11:00 AM | SESSION 3 - MEDICAL DEVICES



4Tissue is a research-driven clinical development company revolutionizing tissue reconstruction, regeneration, and anti-aging. Using cutting-edge biocompatible and bioresorbable polymer technology, we are redefining regenerative medicine. Our lead product, a bioresorbable injectable hydrogel, enhances cell survival and fully regenerates adipose tissue, offering a safer, more effective breast reconstruction option after cancer treatment. This minimally invasive solution supports natural cell regeneration, enabling the body to restore tissue with durable, predictable results. To advance our mission, 4Tissue is currently fundraising for a Series A round to initiate the first-in-human study. Our goal is to bring this groundbreaking innovation to patients, improving lives worldwide. By leveraging breakthrough biomaterials, we aim to set new standards in regenerative medicine, empowering women with safer, more effective reconstructive options.



ArthroSave is a Dutch orthopedics company which has developed a unique solution to improve osteoarthritic joints, allowing patients to return to an active way of life. The CE-certified KneeReviver has demonstrated significant pain reduction, functional improvement and cartilage regeneration across multiple clinical studies. The long term data show that the KneeReviver treatment postpones the knee replacement with 10 more years. Gearing up for the next step, ArthroSave is raising EUR 5M to fund its commercialization in Europe, with the option to increase the investment to enable US market access. Currently, we are actively speaking with investors to realize this round and are keen to discuss our proposition with you in more detail. Are you available for a meeting in Barcelona?



Robopedics designs and produces the first bionic walking system for stroke survivors wheelchair-bound for life. Our purpose is to improve the quality of life of more than 20 million people worldwide, as well as to shape the future of rehabilitation. This is a 1 billion business and we are just a few months away from certification and the first sales. We have already secured our first distribution agreement with the largest rehab chain in Spain.



At Ysium Medical, we develop innovative medical devices to transform the healthcare sector, ensuring their delivery to hospitals through collaboration and licensing with leading global companies for commercialization. We work close together with universities and key opinion leaders in health areas to develop innovative products, in fields like oncology, neurology and simulation. We are growing faster being closer to the go to market in some of our products, actually immerse in some clinical trials and developing.



## 1:00 PM | SESSION 4 - THERAPEUTICS



CCRP Therapeutics is a Berlin-based biotech company pioneering first-in-class, bioavailable small-molecule blockers of the (pro)renin receptor (RERBs). These innovative therapies offer a tumor-agnostic, multi-pathway approach to treating solid tumors by targeting a key upstream regulatory node. By simultaneously impacting multiple pathways, RERBs maximize efficacy across diverse cancer types while providing unique cardio- and renoprotective benefits - addressing critical side effects common in current oncology treatments. This novel approach has the potential to transform cancer care and expand into cardiovascular and renal disease applications.



Cebiotex is an innovative biotechnology start-up, a spin-off from the Universitat Politècnica de Catalunya (UPC) and the Hospital Sant Joan de Déu de Barcelona (HSJD). We are transforming adult and paediatric surgical on-cology by solving local control of remaining cancer cells after surgery. The company has developed a unique proprietary combination of nanofiber technology and patented formulation of SN-38 (irinotecan active metabo-lite) to be locally delivered at the tumour bed. The technology has demonstrated positive Phase 1 data in retro-peritoneal Soft Tissue Sarcoma, with an excellent safety profile and promising efficacy signals. Currently, the team has initiated Phase 2 trial in non-metastatic Pancreatic Cancer, a disease with high unmet medical need and a 5-year relative survival rate of only 44%. By providing innovative biomedical solutions, we aim to support surgeons in improving outcomes and enhancing the treatment and quality of life for cancer patients.



LeadArtis is a biopharmaceutical company engaged in the development of proprietary therapeutic antibodies named Trimerbodies with higher multivalence and multispecificity than the immunoglobulins, which are currently most prevalent on the market. Our drug candidates are derived from in-house R&D and our collaborations with reference research centers and other companies. We have several proprietary programs developing in multiple therapeutic areas, including immunoncology, which is a high-growth area for companies and investors. LeadArtis offers an opportunity to participate in the development of cutting-edge immunomodulatory therapies against cancer. Trimerbody® is a registered trademark and is covered by international patents.



OncoLize (Leiden, the Netherlands) develops a portfolio of injectable drug depots for localized, intra-tumoral drug-delivery of well-known and novel drugs. The company demonstrates precision in targeted delivery: up to 125x higher drug concentration on target, up to 400x smaller doses in total, very low (100-1000x) drug levels outside the tumor... Strong P-o-C in pancreatic cancer mouse models using human biopsy: 100% survival, no adverse side effects, for pancreatic- and lung-cancer cell lines in vivo. Preparing Clinical trials with world top KOL's and Patient advocacy org in Pancreatic cancer Strong base patents granted in USA, EU, China and Japan with more to come. Highly experienced team is raising US\$ 23 Mln in 2 steps of US\$ 4 and US\$ 19 mln the first half 2025 to finalize IND/IMPD, apply for Orphan Drug Designation and enter clinical trials in US, EU and Australia by 2026. Next: Gastric, Colon, Lung, Breast, Bladder, Prostate.

## 2:00 PM | SESSION 5 - BIOTECH THERAPEUTICS



Ablevia has developed an innovative platform of injectable molecular decoys designed to efficiently capture and eliminate harmful anti-drug and anti-vector antibodies from the bloodstream. By pre-treating with Ablevia's adaptable antibody-removing decoys, a therapeutic window is created for administering therapeutics impacted by anti-drug, anti-Polyethylene Glycol (PEG), or anti-vector antibodies. This solution spans a wide range of therapeutic fields, including cancer, rare diseases, and gene therapies. Notably, Ablevia's flagship drug targets and removes anti-PEG antibodies, overcoming a major challenge for PEGylated drugs and nanocarriers.



Amarna Therapeutics has developed a groundbreaking non-immunogenic viral platform to deliver any transgene of choice into humans. Nimvec™ AM510 is a tolerance inducing gene therapy for the treatment of Type 1 Diabetes. Diabetes is an autoimmune disease where self-reactive T lymphocytes selectively attack and destroy insulin-producing  $\beta$  cells lodged within the pancreas, leaving the patient unable to maintain glucose homeostasis. Proinsulin (PI) is considered to be the primary self-antigen involved in the autoimmune  $\beta$  cell destruction. To date, Type 1 Diabetes cannot be cured and the glucose homeostasis can be more or less maintained in patients by daily insulin injections. Although Diabetes is seen as a manageable disease nowadays, secondary complications of the current therapy are considerable and lead to significant morbidity and mortality. Using Nimvec™ AM510 we intend to restore the immune tolerance to proinsulin and potentially cure the patients.



Cellevate is a Swedish biotech based on innovative, sustainable, green, proprietary nanotechnology for large scale biomanufacturing of novel biotherapies i.e. cell & gene therapy and novel vaccines. The ongoing biomanufacturing revolution has started in 2022 due to the prohibitive price tags of 1 MEUR per dose for these miracle cures. Biopharmas and CDMOs are looking to implement new disruptive technologies providing high yields, scalability and productivity to decrease the cost of production of these medicines. In November 2024, Cellevate launched world's 1st nanofiber-based cell culture systems providing 300% productivity increase for gene therapy large scale bioreactor production compared to current standard processes. These sustainable products provide faster bioprocessing, more efficient scale up and more than 3 times higher yields that ultimately lead to 70% reduction of cost of production for 2000 L process. We are already selling to pharmas and CDMOs and we are aiming to breakeven in 2028.



Oral route is the preferred way for drug administration for patients, manufacturers and Healthcare Systems. Biologic drugs are still limited to injected delivery: costly and unsustainable as their use grows. Oral accessibility is a major unmet need for biologic therapies. GATBIO is a biotech company devoted to delivering oral biologic therapies for intestinal diseases. Our mission is the accessibility of oral biologics: replacing current costly injected biologics with daily oral pills solutions. GATBIO's proprietary plug&play platform - GRTTM - delivers a new class of antibodies engineered for stable activity at room temperature and in the harsh intestinal atmosphere enabling their oral non-refrigerated administration. GB-AF-004 - GATBIO's lead candidate (preclinical stage): is an efficient inflammation blocker orally delivered to the damaged intestinal tissues to act locally and avoid systemic distribution site-effects and rejection issues. Our portfolio targets key players in the intestinal inflammatory cascade for long-term, safer and personalized next-gen IBDs therapies.

## 3:00 PM | SESSION 6 - MEDICAL DEVICES



CYTO365 have developed the product RondelO which is the first and only selector valve that provides a physical barrier toward unintentional drug mixing in infusion therapy. Typically there are multiple drugs used to treat cancer but they should only be given one at a time with flushing fluid in between. If they are mixed drug incompatibility can occur with adverse event. RondelO solves this problem by allowing multiple drugs to be connected at once to the RondelO selector valve, but only one drug can flow to the patient at a time and is selected with the RondelO handle. It provides a safe closed circuit that also limits exposure of hazardous drugs to the nurse.



Our company is based in Alicante, Spain, and is focused on a novel medical device invented and patented by our founder, Dr Fernando Godoy. The scope of our device, excellgraft, is to offer a fast and reliable method to process fat graft, both for reconstructive and cosmetic indications, but focused on safety as our first and most important principle. Other devices offer this solution but are exclusively focused on sterility and ease of use for the operating surgeon. Our device outperforms existing commercial devices and achieves a safer solution for the patient.



MiWEndo is redefining colorectal cancer detection by integrating microwave imaging with colonoscopy to detect what optical methods miss. Colorectal cancer is the second leading cause of cancer-related deaths worldwide, and up to 22% of polyps go undetected with current techniques. MiWEndo's patented, AI-enhanced technology seamlessly integrates with standard colonoscopes, providing real-time, 360° tissue analysis to improve detection rates, especially for challenging flat polyps. Our device has already demonstrated near 100% sensitivity in ex vivo studies, and our pivotal clinical trial is underway to support CE Mark approval by late 2025. MiWEndo is backed by leading investors, research institutions, and gastroenterology experts, with growing industry interest. As we prepare for commercialization, we are actively engaging with distributors, strategic partners, and investors to accelerate market entry. Join us in bringing a breakthrough solution to colorectal cancer screening and saving lives.



Samplix develops cutting-edge microfluidics solutions — including instruments, consumables, and software — for life sciences and medical research. Our technology enhances resolution and throughput in functional single-cell analysis, providing deep insights into cell heterogeneity. With applications in cell therapy, immunotherapy, synthetic biology, and oncology, our platform seamlessly integrates with single-cell sequencing, enabling unprecedented correlation between function and molecular profiling. By enhancing the performance of 200,000 existing flow cytometers, cell sorters, and imaging systems, our market opportunity is both significant and immediate. Currently in early commercialization, Samplix has secured partnerships with leading life science tool providers, including Agilent and Thermo Fisher. Backed by a prestigious €10 million EIC grant, with €7.5 million allocated for investment in our next funding round, we are well-positioned for growth.

# 9:00 AM - 2:50 PM | INNOVATOR'S PITCH CHALLENGE TRACK 2

Location: Rossini 2 (Main Level)

## Pitch Company

9:00 - 9:50 AM

### IPC SESSION #7 DIAGNOSTICS



Table #1



Table #6



Table #25



Table #2

10:00 - 10:50 AM

### IPC SESSION #8 DEVICES & DIGITAL HEALTH



Table #36



Table #3



Table #8



Table #30

11:00 - 11:50 AM

### IPC SESSION #9 DIAGNOSTICS



Table #26



Table #7



Table #15



Table #5

1:00 - 1:50 PM

### IPC SESSION #10 MEDICAL DEVICES



Table #20



Table #29



Table #37



Table #35

2:00 - 2:50 PM

### IPC SESSION #11 THERAPEUTICS & MEDICAL DEVICES



Table #14



Table #44



Table #38



Table #32



## 9:00 AM | SESSION 7 - DIAGNOSTICS



Our company has developed an IVD, the MAP-AD Test, the first that predicts the progression from Mild Cognitive Impairment to AD Dementia through novel blood-based mitochondrial biomarkers using NGS techniques and a ML approach. The MAP-AD Test will be provided to pharmaceutical companies for optimizing clinical trials, and to Hospitals for assessing the eligibility of patients for beta-amyloid therapies. The company holds the ISO13485 and it is expected to obtain the CE marking next April 2025. Moreover, the company recently achieved the laboratory CAP-accreditation. First sales are forecasted from Q3 2025 and different feasibility studies are going to be activated in three hospitals in Spain and in Kansas from Q2 2025. In addition, the analytical validation is being completed for the FDA submission in Q1 2026. The company has an open ?10M equity round to cover the first sales in Europe and US.



Altratech (Ireland) has a multidisciplinary team of 17 scientists and engineers with expertise in microfluidics, chip design, biology, physics and chemistry. Our novel Multianalyte DNA/RNA/Antibody/Antigen Diagnostic is protected by 40 proprietary patents granted worldwide. We also hold one patent jointly with the U.S. National Institute of Health, on PNA probe design and synthesis. Altratech's promoters have strong track records in microfluidics and in chip design and have built and sold previous companies to Life Technologies and Silicon Labs. To date Altratech has raised circa US\$20M, including from EU Horizon 2020 and US BARDA DRIVE programs. Investors include Kernel Capital, Infinity Capital and Claret Capital. In 2024 Altratech was a successful applicant to the EU/EIC prestigious Accelerator Program and awarded ?10.5M towards clinical-trial validation in St.Cecilio Hospital (Spain). The Company is now seeking a strategic partner from within the life science industry and is open to investment and licensing arrangements.



Early diagnosis of cancer by liquid biopsy applied to veterinary medicine. We are helping to increase the life expectancy of dogs with cancer by giving the veterinarian more time to act more effectively before the disease manifests itself. Our minimally invasive diagnostics are based on a liquid biopsy and enable early detection of the major cancers in a single analysis. The company is also exploring a new line of research related to the search and validation of breast cancer biomarkers identified in dogs that could be licensed for use in humans through comparative oncology.



Flomixics Biotech is developing a revolutionary liquid biopsy test that is capable of detecting multiple types of cancer with high accuracy and with the convenience of a standard blood extraction. By combining Genomics and Artificial Intelligence we detect molecular patterns associated with the disease that are capable of directing diagnosis even before the first symptoms appear. By detecting cancer in early stages, we make sure everybody gets the best odds to win the battle against this devastating disease.

## 10:00 AM | SESSION 8 - DEVICES & DIGITAL HEALTH



Discover MICHELANGELO, our new generation rolling walker with autonomous walking assistance. It has been designed to provide the complete safety you need to move around freely and get through your day entirely independently. Our innovative active fall prevention system enables MICHELANGELO to detect a loss of natural posture in the user's body, to act automatically and to correct that posture so as to avoid falls thanks to real-time monitoring of the situation on the ground and the physical conditions of the user. In the end, we aim to deliver three major advantages to our users and their loved ones: 1. Enhanced Safety: Offers stability and dynamic support at all times, encouraging safer and more independent mobility. 2. Frictionless Design: No buttons or levers are required for operation, facilitating the user experience. 3. Connectivity: Allows the user's activity to be monitored and alerts to be sent in case of emergency.



We empower pharmaceutical companies and healthcare providers with validated digital biomarkers to precisely measure disease progression and treatment efficacy. Ephion Health is a digital health startup created in 2021 in Barcelona as a spin-off of Eurecat and Sant Joan de Déu Hospital. We develop digital biomarkers to ensure accurate disease monitoring and therapy assessment. We use an AI-based platform to analyze data from 3rd party wearables and generate clinically validated digital biomarkers that quantify a patient's condition. Our first product, Ephion Mobility, is focused on neuromuscular diseases and is a certified Software as a Medical Device under MDR and is FDA registered. Ephion aims to partner with pharmaceutical companies to use our digital platform to co-develop new digital biomarkers that de-risk clinical trials and improve the efficiency of drug development.



Geneial is a secure global biomedical data network that connects patients, researchers, diagnostic labs, and healthcare systems to advance precision medicine while preserving privacy and data integrity. We accelerate research, development, and commercialization in genetic medicine by streamlining patient recruitment, integrating deep phenotyping with patient-reported outcomes, and leveraging secure agentic AI to automate data mapping to standardized analysis-ready formats. This reduces the time spent on data cleaning and structuring, allowing researchers to focus on analysis and discovery. By ensuring interoperability with clinical and research databases, we help translate genomic data into actionable insights faster. With a focus on privacy-preserving technologies and data stewardship, Geneial supports a more connected and equitable future in genomic medicine, ensuring that valuable data remains accessible, actionable, and secure.



Kardi Ai is revolutionizing heart health with cutting-edge AI-driven monitoring. Our wearable solution provides continuous ECG analysis, detecting irregularities early and enabling proactive care. With a CE-certified medical device and an intuitive app, we empower users to track their heart health effortlessly while giving doctors valuable insights to optimize treatment. Kardi Ai has already helped save over 220 lives and continues to expand globally. Designed for both individuals and healthcare professionals, our technology enhances prevention, speeds up diagnosis, and reduces the burden on medical staff. Stay ahead of heart disease? anytime, anywhere.

## 11:00 AM | SESSION 9 - DIAGNOSTICS



Eversens designs, develops, manufactures and commercializes a suite of diagnostic and prognostic medical devices and software solutions for the analysis of biomarkers in human breath, leveraging proprietary sensor technology and AI for predictive analytics, across global chronic disease areas, such as Asthma and COPD. Eversens is based in Pamplona, Spain and our CE-marked technology is currently in use by clinicians and patients in 19 countries across EMEA, APAC and LATAM and pending FDA in the US.



myBiometry empowers people with respiratory disease by providing proactive, actionable data to prevent attacks. We focus on early detection of asthma/COPD attacks up to 20 days in advance using intelligent diagnostics and connected monitoring. Attacks drive adverse outcomes and costs, totaling \$130B annually in the US and affect over 1B people worldwide. For patients, attacks are life-altering, requiring immediate intervention and causing long-term lung damage and severe side effects from frequent steroid use. Current monitoring methods detect deterioration too late for effective intervention. Our solution predicts attacks up to 20 days before symptoms by combining a patented sensor, a connected device, and an app to measure FeNO, a biomarker of airway inflammation. FeNO is a recognized risk factor for attacks and is included in US and global asthma guidelines for diagnosis and monitoring.



NIMBLE Diagnostics has developed a microwave-based cutting-edge technology for non-invasive, real-time monitoring of metallic implants, with its first application focused on cardiac stents due to our strong roots in cardiology. Our innovative WAEVE system uses electromagnetic resonance to detect implant-related complications, such as blockages, fractures, and restenosis, with 100% sensitivity and 92% specificity demonstrated in our pre-clinical and first-in-human trials. This portable and cost-effective device is compatible with all stent types, enabling proactive monitoring and reducing the need for invasive procedures like angiography. While our initial focus is on cardiovascular stents, addressing a critical unmet need for over 50 million patients globally, our technology is designed to monitor a wide range of metallic implants, including orthopedic prostheses and bioabsorbable devices. With potential applications in industrial quality control and home monitoring, NIMBLE is poised to revolutionize implant care, setting a new standard for patient outcomes and healthcare efficiency worldwide.



POROUS offers a unique 3D ultrasound solution for cortical bone microstructure parameters. Our mission is the early and accurate diagnosis of osteoporosis to allow for timely interventions to prevent fractures, to empower women's and men's bone health & healthy aging.

POROUS ultrasound device features a dedicated software for the assessment of cortical bone microstructure intended to provide clinical researchers in academia and pharma/biotech with a novel tool to study metabolic bone disorders, ranging from widespread osteoporosis to rare bone diseases. POROUS enables low-cost, non-radiation measurement of dynamic biomarkers so far only accessible by high-cost HR-pQCT. POROUS validates its ultrasound solution for early and accurate diagnostic of osteoporosis.

Main achievements:

2021 – Founded as Spin-Off of Charité Universitätsmedizin Berlin

2021 – ISO 13485 certification

2022 – EIC Accelerator grant recipient

2024 – Market entry & first sales of measurement device

2025 - Multicenter international confirmatory fracture risk prediction evaluation study started

## 1:00 PM | SESSION 10 - MEDICAL DEVICES



BOYDSense, an award-winning start-up developing non-invasive breath analysis solutions to risk stratify, monitor and detect biomarkers for chronic conditions and diseases, focusing initially on Diabetes. The first product to market is a miniaturized breath analyzer to monitor glucose levels in pre-diabetics and type 2 diabetics non-invasively. Unlike existing blood glucose monitors, our solution is pain-free, affordable and produces significantly less waste. The product is currently under development with 64 active projects on device development, further clinical trials ongoing, Quality and Regulatory affairs in Europe and US, Industrial Design and UX/UI etc. So far €18m has been invested in BOYDSense, in the last €7m round 2024 the European Innovation Council fund, Swiss Diabetes Venture fund and BioSerenity invested beside Jolt and Ambrosia. BOYDSense is currently raising money again and looking for a lead investor.



EndoPLY makes an endoscopic medical device meant for inner restriction of the stomach in obesity treatments. It competes with similar MD from Boston and USGI Medical, but also with bariatric surgery and new drugs (GLP1 agonists). It has ergonomic advantages and a low environmental footprint. First-in-human is scheduled in March 2025 (Pilot study, 10 pts, Czech Republic). We have already raised 850 KE (including a French BPI subvention of 300 KE). Kick-off for CE-mark application has started in Dec 2024, we expect a return at the end of S1 2026, preceded by a pivotal multicenter study and sales by the end of 2026. 1200 Units X 3500€ are expected in 2027, with profitability at that time. We wish to raise 4-5 M, including a 1 M French government subvention for the "premiere usine (first factory) -France 2023 grant.



Interlinked – Transforming IV Therapy and Nephrostomy Drainage Interlinked is a medtech company dedicated to improving patient safety and healthcare efficiency. Our innovative, clinically proven device, ReLink, is a breakaway connector designed to prevent catheter dislodgement, a critical issue in IV therapy and nephrostomy drainage. By reducing accidental disconnections, ReLink minimises complications, infections, and additional interventions, leading to better patient outcomes and significant cost savings for healthcare providers. ReLink is patented, CE MDR Class II certified, FDA Class I registered, ensuring compliance with the highest regulatory standards. With over 2,000 devices used on patients and ready to fulfil new orders, we are positioned for rapid growth. With 16 billion IV lines placed annually and millions of patients relying on nephrostomy drainage, the impact of ReLink is enormous. We have already invested in scaling production and are focused on increasing sales and reducing COGS to drive market adoption and long-term profitability.



Opportunity Health is a company dedicated to the development of Opportunity, an innovative medical device designed for automatic and self-applicable de-choking. Its objective is to provide an effective solution to choking emergencies, reducing the risk of death in these cases. We are currently in the development and validation phase, with key collaborations with the University of Navarra and the Santiago de Compostela Health Research Institute (IDIS). In addition, we participate in acceleration programs such as CEIN Health and BerriUp, and we continue to advance in regulatory compliance to obtain the CE marking.

## 2:00 PM | SESSION 11 - THERAPEUTICS & MEDICAL DEVICES



Anaconda Biomed, a Barcelona-based medical device company, specializes in innovative solutions for Acute Ischemic Stroke (AIS) treatment. Its flagship product, the ANA (Advanced Neurovascular Access) Funnel Catheter, improves Mechanical Thrombectomy by enhancing clot removal efficiency. Inspired by the anaconda snake, the device features a self-expanding, radiopaque, coated braid, allowing it to adapt to artery size while restricting blood flow to optimize clot retrieval and minimize fragmentation. The ANA Funnel Catheter demonstrates superior navigability and safety, achieving a 61% first-pass effect (FPE), compared to the standard <45%. Clinical trials, such as the ANAIS study, reported a 90% reperfusion rate (mTICI 2b/3) within three passes, with no serious device-related adverse events. Additionally, ANA reduces symptomatic intracerebral haemorrhage risk, with no cases reported at 24 hours post-procedure. By addressing key thrombectomy challenges, Anaconda Biomed is advancing stroke treatment with more effective and safer solutions.



NEWRO is a cutting-edge hybrid brain-machine interface designed for upper limb motor rehabilitation, even in the most severely affected stroke patients. By combining brain and muscle signals, the system interprets movement intentions and translates them into real-time exoskeleton-assisted actions, reinforcing neuroplasticity for functional recovery. Unlike conventional therapies, NEWRO enables full-arm, wrist, and hand rehabilitation in an integrated approach. Its AI-driven adaptability personalizes training intensity and progression, while gamification enhances patient engagement. With a strong clinical foundation - 40 stroke patients across three trials—NEWRO has demonstrated its potential for significant motor recovery. As the stroke incidence rises, NEWRO targets private rehabilitation clinics and, later, insurers and public healthcare systems. With a scalable business model and a competitive advantage over existing solutions, NEWRO is well-positioned to transform stroke rehabilitation, offering a scientifically validated, cost-effective, and comprehensive solution to a growing global challenge.



Rhythm Biotherapeutics Inc. is an innovative biotech startup pioneering the development of natural atrial exosome-based therapies to prevent and treat atrial arrhythmias, including atrial fibrillation. As a spinout of the University of Ottawa Heart Institute, the company leverages cutting-edge research and patented manufacturing methodologies to produce heart-derived extracellular vesicles (EVs) enriched with microRNAs and proteins that reduce inflammation, suppress fibrosis, and promote tissue regeneration. With a focus on quality and scalability, Rhythm Biotherapeutics conducts cell manufacturing in a GMP-certified facility and is actively advancing toward Phase 1 clinical trials. The company's preclinical studies demonstrate efficacy across small and large animal models, showing profound anti-inflammatory effects without adverse immune reactions. By harnessing the therapeutic potential of exosomes, Rhythm Biotherapeutics is poised to transform the landscape of atrial arrhythmia management, offering a safe, effective, and biologically inspired alternative to traditional treatments.



Every year, >200,000 patients undergo treatment for Abdominal Aortic Aneurysm with >75% using EndoVascular Repair (EVAR). While EVAR offers immediate benefits, these are offset by the need for frequent reinterventions. TripleMed's groundbreaking Sac Filling technology addresses this challenge. Our innovative AneuFix polymer is injected around the stent graft following implantation, creating a cured elastic implant, taking away pressure in the sac and thereby sac growth. This significantly reduces the need for reinterventions, providing a simple, durable, and cost-effective solution that enhances patient quality of life while delivering substantial savings to hospitals and insurers within this \$1.2B+ AAA market. AneuFix is currently undergoing clinical trials in Europe, with 100% technical and clinical success for the Sac Filling application. A CE Dossier is submitted for the endoleak repair application. We are now seeking €13 million to fund a RCT in EU and US for Sac Filling to obtain CE and FDA-PMA



# 9:00 AM - 2:50 PM | ENTREPRENEUR'S WORKSHOPS

Location: Vivaldi 2 (Main Level)

## Presenters

9:00 - 9:50 AM



### IT ALL STARTS WITH YOUR STORY

**Dennis Ford**, Founder and CEO, Creator of RESI Conference, Architect LSN Labs  
**Greg Mannix**, VP of International Business Development, Life Science Nation

10:00 - 10:50 AM



**Ekke van Vliet**, Investment Coordinator, European Innovation Council

11:00 - 11:50 AM




**Carmen Ríos**, CEO, Doctomatic  
**Ramon Maspons**, Chief Health Innovation Strategist. Ministry of Health, Government of Catalonia  
**Meike Bomhof**, VP Market Access, Avania  
**Ana Maiques**, CEO, Neuroelectrics  
**Francisco Rodríguez**, Medical Device Manager and Lead Auditor, Asphalion

1:00 - 1:50 PM

### TALES FROM THE ROAD

Biotech and MedTech Innovators  
on their Fundraising Journey

**Greg Mannix**, VP of International Business Development, Life Science Nation   
**Robert Lauritzen**, CEO, Cerebriu  
**Nick Sireau**, CEO, Serenatis Bio  
**Valerie Vanhooren**, Co-founder & CEO, ONA Therapeutics

2:00 - 2:50 PM



**Patrik Frei**, Founder & CEO, Venture Valuation AG, Switzerland

3:00 - 3:50 PM



**Amador Rodríguez Martín de la Fuente**, Corporate Lawyer, Cuatrecasas  
**Guillem Masferrer**, VC, Asabys Partners  
**Xavier Morera**, Senior Associate, M&A, Private Equity & Venture Capital, Corporate Law, Cuatrecasas

4:00 - 4:50 PM



### GLOBAL PARTNERING CAMPAIGN INVESTOR LANDSCAPE, GTL AND CRM/GPC

**Claire Jeong**, COO, VP, Investor Research & Asia BD, Life Science Nation  
**Karen Deyo**, VP of Product, Israel Business Development, Life Science Nation



Moderator

## 9:00 AM | IT ALL STARTS WITH YOUR STORY PREPARING FOR A GLOBAL ROADSHOW

The most successful entrepreneurs are always the best storytellers. Finding a way to naturally formulate your company's unique story and portraying this through multiple modalities whether it be a 1-minute elevator pitch or a 12-slide pitch deck is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook. Investors always bet on the team, not just the technology, and if every member of your startup can tell any strategic partner a consistent story of your company and technology, you are on the right track to building successful relationships.

### **Dennis Ford, Founder and CEO, Creator of RESI Conference, Architect LSN Labs**



Dennis Ford is an entrepreneur, author, and frontier technologist with deep expertise in sales, marketing, and business development. Dennis has spent a decade in the early-stage life science arena creating a partnering platform that matches next-generation drugs, devices, diagnostics, and digital health products with investor and licensing partners. Dennis has developed an active network of global investors ranging from Family Offices, Private Equity, Venture Capital, Foundations, and Endowments to large Corporate and Pharmaceutical firms interested in high-growth early-stage technologies. Dennis has also pioneered a unique global partnering event called the Redefining Early-Stage Investments Conference Series that matches investors and licensing partners with startup firms based on stage of development and product.

Dennis is the author of *The Peddler's Prerogative* and *The Fund Manager's Marketing Manifesto*, two well-received sales and marketing books. His latest book is *The Life Science Executive's Fundraising Manifesto* which he turned into a two-week immersion class for scientist-entrepreneurs and fundraising CEO which is now offered to help launch and fund startups into the global life science arena.

### **Greg Mannix, VP of International Business Development, Life Science Nation**



Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master's degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in large medical device corporations and small start-ups alike, giving Greg a well-rounded international experience in the healthcare field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg relocated to Boston 6 years ago to set up the US affiliate for an early-stage Med-tech company from Spain and he immediately took to the vibrant startup community there. Working for LSN is a great way to stay involved in that exciting space.



## 10:00 AM | THE EUROPEAN INNOVATION COUNCIL (EIC)

This workshop on the EIC will explain which support the European Commission provides to European deeptech start-ups. The EIC Accelerator facility, for start-ups the most relevant instrument, will be discussed in more detail.

### **Ekke van Vliet, Investment Coordinator, European Innovation Council**



Ekke is a business economist and auditor by education and experience, with a career spanning more than two decades in various financial roles in the European Institutions. Since 2019 Ekke has been involved in the set-up and operations of EIC Fund, the venture capital initiative of the European Commission investing in deep tech European start-ups. The EIC Fund started operations in 2020 and has already invested in more than 260 start-ups with a total commitment of €2.4bn set to grow to €4bn by 2027. His focus at this moment is supporting the start-ups in the EIC portfolio with fundraising and commercial development maintaining relations with a wide range of investors and corporates.

To explore the challenges and strategies in achieving market access for healthtech innovations, focusing on regulatory hurdles, coverage, coding, reimbursement and adoption pathways, and the role of data and digital tools in healthcare.



**Carmen Ríos, CEO, Doctomatic**

Carmen Ríos holds a degree in Slavic Languages, Literatures, and Linguistics from the University of Barcelona (UB) and is an expert in digital transformation, having worked in various high-pressure roles in technology — both as an entrepreneur and in setting up international operations for Blue-Chip companies. She currently works at the intersection of technology and healthcare as the CEO & Co-Founder of Doctomatic, an AI-powered software that converts medical device images into data.



**Ramon Maspons, Chief Health Innovation Strategist. Ministry of Health, Government of Catalonia**

Ramon Maspons Bosch holds a degree in Industrial Engineering from the Polytechnic University of Catalonia (UPC). He is currently the Strategic Director of Health Innovation at the Department of Health of the Government of Catalonia and Head of Innovation at the Agency for Quality and Health Assessment of Catalonia (AquAS). Maspons has over thirty years of experience in hospital and medical innovation, as well as in internationally funded research projects.




**Meike Bomhof, VP Market Access, Avania**

Meike has over 30 years of global medical technology experience, as well as a Masters Degree in Healthcare Assessment and Market Access, and an international postgraduate diploma in health economics and business administration, international marketing. Currently, Bomhof is the Vice President, Market Access of Avania in Europe.



**Ana Maiques, CEO, Neuroelectrics**

Ana Maiques is the CEO of Neuroelectrics, a company aiming to change the way we interact with the brain, developing innovative technologies to monitor and stimulate the brain to help many patients in need. She was nominated by IESE as one of the most influential entrepreneurs under 40 in Spain (2010) and received the EU Prize for Women Innovators from the European Commission EC in 2014 and one of the Most Inspiring Fifty Women in Europe. Neuroelectrics recently received the Best Start-up in Health 2015 by Wired UK magazine in an amazing event in London.



**Francisco Rodríguez, Medical Device Manager and Lead Auditor, Asphalion**

Francisco Rodríguez holds a degree in Basic and Experimental Biomedicine from the University of Seville (US). He is currently a Medical Device Manager and Lead Auditor at Asphalion and has been awarded a grant from the Government of Catalonia to conduct his doctoral thesis on Regulatory Science within the Medical Devices team of the company.

The industry has quickly adapted to a “new normal” – entrepreneurs and investors meet virtually over digital platforms to discuss potential investment opportunities, and it is not uncommon to see entrepreneurs raise capital from investors they have never met before in person. That said, there is no doubt that the fundraising journey continues to be challenging for many. In this panel, you will be able to hear fellow entrepreneurs share their experiences, from successes to challenges. This panel will discuss the following topics and more:

- What are some of the greatest challenges entrepreneurs have faced, especially during the pandemic, and how were they overcome?
- How did entrepreneurs identify investors that fit their technology?
- What are some misconceptions entrepreneurs had about the early-stage investment landscape?

Furthermore, entrepreneurs will share unique tips and insights they have gained from their fundraising experiences, and how others can work their way towards a more successful campaign.

## Greg Mannix, VP of International Business Development, Life Science Nation



Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master's degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in large medical device corporations and small start-ups alike, giving Greg a well-rounded international experience in the healthcare field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg relocated to Boston 6 years ago to set up the US affiliate for an early-stage Med-tech company from Spain and he immediately took to the vibrant startup community there. Working for LSN is a great way to stay involved in that exciting space.



## Robert Lauritzen, CEO, Cerebriu

Robert is the CEO and co-founder of Cerebriu and former international IT life sciences executive with 25+ years of management experience across high-tech, medtech, large corporations and startups across pharma and IT service providers, building and managing global delivery and sales execution across Europe, North America and Asia. He brings a strong track record of strategic leadership and innovation, with a passion for transforming healthcare through intelligent technology solutions.



## Nick Sireau, CEO, Serenatis Bio

Nick Sireau, PhD, is the CEO and Co-founder of Serenatis Bio, a biotech focusing on developing new medications to treat obsessive-compulsive disorder (OCD), a common yet poorly treated and devastating disorder that he suffers from himself. He is also co-founder and Chair of Orchard OCD, a medical charity that funds academic research into OCD. Nick runs a support group for people with OCD where he lives in Cambridge, UK.



## Valerie Vanhooren, Co-founder & CEO, ONA Therapeutics

Valerie is co-founder and CEO of Ona Therapeutics. Since 2019 she has guided the growth and development of Ona's pipeline of first-in-class in ADCs and antibodies and secured over 35 million euros from a syndicate of international investors and non-dilutive grants. She has extensive experience in discovery and development of antibodies and protein conjugates for oncology. Prior to Ona she held leading R&D roles at SpliceBio and Ablynx (acquired by Sanofi), where she led drug development collaborative partnerships with multiple internationally operating pharmaceutical entities, including Merck and AbbVie. Valerie holds a PhD in Biotechnology from the University of Ghent, Belgium.

Valuation is a key aspect of fundraising. An average value assumption for each company in a specific financing stage just does not do it anymore. For entrepreneurs, as for investors, it's important to understand the value drivers of a company. We are looking at the financing trends of the last years, discuss dos and don'ts when speaking with investors and look at how to value a life science company with no revenues.

### **Patrik Frei, Founder & CEO, Venture Valuation AG, Switzerland**

Dr. Patrik Frei is founder and CEO of Venture Valuation AG, Switzerland. He started the company in 1999 when he noticed a need for independent valuation services in high growth industries during a collaboration with Novartis Venture Fund, which became his first client. Since then he has been involved in over 450 valuations for investors as well as biotech, Pharma and medtech companies. Patrik graduated from the Business University of St. Gallen and completed his PhD thesis ("Assessment and valuation of high growth companies") at the Swiss Federal Institute of Technology, EPFL Lausanne. Patrik was a board member and one of the original founders of Ineo, a holding company of the Swiss dental implant VC-backed firm Thommen Medical and also the Chairman of Ophthalmopharma, a Swiss based biotech ophthalmology company, where he successfully out-licensed a portfolio of 4 products. Furthermore, Patrik was member of the board of Aventron AG (AVEN:Berne) a publicly quoted cleantech company, which raised over USD 160m during his time as board member. Patrik's articles have been published in a number of scientific journals including "Nature Biotechnology", "Chimia" and other business publications ("Starting a Business in the Life Sciences: From Idea to Market" and "Building Biotechnology: Starting, Managing, and Understanding Biotechnology Companies"). He has also lectured at Seoul National University, South Korea, EPFL Lausanne, University of St. Gallen and gives regular workshops on valuation.



## 4:00 PM | GLOBAL PARTNERING CAMPAIGN INVESTOR LANDSCAPE GTL AND CRM/GPC


Once you are ready to embark on your fundraising campaign, how do you know whom to target? What investors are a best fit for you, how do different investors invest and partner, and how do you get in touch with them? Identifying investors, learning about the differences between investor types, accessing a database to provide you with key information to filter your best fit investors, and finally, using a CRM to manage your fundraise are critical to an efficient and successful fundraise.

### **Claire Jeong, COO, VP, Investor Research & Asia BD, Life Science Nation**



At Life Science Nation (LSN), Claire leads the Investor Research team that is responsible for curating the LSN Investor Platform. Claire manages relationships with a wide network of investors, pharmaceuticals, and other strategic partners across the globe. As Asia BD, Claire is responsible for building LSN's network in Asia with a strong focus in South Korea and Japan. Since 2018, she has been working with numerous organizations in South Korea, leading collaboration efforts to bring a large delegation of Korean start-ups to the Redefining Early Stage Investments (RESI) Conference, an early-stage life science investment focused partnering conference organized by LSN, supporting their global expansion efforts. Claire is also heavily involved with RESI strategy and program development, for which she works on structuring relevant content and work closely with many investors on this front. Claire is also the team lead for the Innovator's Pitch Challenge (IPC) and oversees all logistics.

### **Karen Deyo, VP of Product, Israel Business Development, Life Science Nation**



Karen Deyo is the VP of Product at Life Science Nation, responsible for new product development and LSN's educational content. In addition to her role as VP of Product, she is actively involved in Israel BD, utilizing her professional and personal connections to connect LSN to the Israeli life sciences startup community. She started out at LSN as part of the investor research team, speaking to investors and learning their investment mandates. Karen utilizes her experience speaking with investors as well as her scientific background to help startups translate their science and prepare for their global partnering campaigns. Karen has a Masters of Engineering in Biomedical Engineering as well as a Certificate in Graduate Business Study from Worcester Polytechnic Institute and a Bachelor of Science degree in Engineering with a concentration in Bioengineering from Olin College of Engineering.





## MEDIA PARTNERS



Want to become a RESI Media Partner? Contact us at [Marketing@lifesciencenation.com](mailto:Marketing@lifesciencenation.com)

### The Life Science Executive's FUNDRAISING MANIFESTO

BEST PRACTICES FOR IDENTIFYING CAPITAL IN THE BIOTECH AND MEDTECH ARENAS  
by Dennis Ford



#### Contributors

Robert Cohen, Tom Crosby, Jack Fuller, Nono Hu, Maximilian O'Connor, Lucy Parkinson, Danielle Silva, and Alejandro



**Download Now ->**

A primary objective for life science executives is raising capital. Very often, however, a lack of marketing and sales skills impedes their efforts. Focusing regionally, rather than globally, only compounds the challenge.

The Life Science Executive's Fundraising Manifesto helps scientists understand the fundamental skills needed to brand and market their companies. It discusses how to use a consistent message to achieve compelling results from a fundraising campaign and it teaches you how to aggregate a list of potential global investors that are a fit for your company's products and services. The book also explains how to efficiently and effectively reach out to potential investor targets, start a dialogue that fosters a relationship, and ultimately secure capital allocations.

Raising capital is not a one-time event. It must be an ongoing part of your business strategy. The Life Science Executive's Fundraising Manifesto reveals the expertise required to continually fundraise and bring your ideas to market.